Open Forum Infectious Diseases · 13 Nov 2026
HIV-1 drug resistance in adults with HIV/TB on rifampicin receiving bictegravir or dolutegravir in South Africa: The INSIGHT trial
Benjamin Chimukangarah-index 14, Jonathan Z Li, Nokuzola Mbhele, Wonderful T Choga, Lateef Babatunde Amusa, Emmanuella Chinonso Osuala, Rubeshan Perumal, Kogieleum Naidoo, Kelly E Dooley, Anushka Naidooh-index 13
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Background Emergence of HIV-1 drug resistance (HIVDR) during bictegravir/emtricitabine/tenofovir alafenamide treatment with rifampicin-based tuberculosis (TB) treatment has not been studied. Methods We analysed plasma samples from INSIGHT (NCT04734652), a phase 2b, open-label, non-comparative, randomised trial in adults with HIV/TB (CD4 ≥50 cells/mm3, ART-naïve or off ART for ≥3 months) receiving twice-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC-arm) or twice-daily dolutegravir with once-daily tenofovir disoproxil fumarate and lamivudine (DTG-arm) during TB treatment in Durban, South Africa. This resistance sub-study used remnant samples to assess emergent HIVDR outcomes. Genotypic testing (Illumina MiSeq) was performed on baseline samples and longitudinally on samples with HIV-1 viral loads ≥50 RNA copies/mL at weeks 24, 40, and 48. Results Median baseline HIV-1 RNA was 4·89 log10 copies/mL (IQR 4·40–5·60) and median CD4 count was 151 cells/mm3 (IQR 99–296). HIV-1 pol genotypes were obtained for 113 participants (74/80 BIC-arm; 39/42 DTG-arm). At baseline, 36/113 (32%) participants had HIVDR mutations at ≥20% frequency, most commonly K103N (61%, 22/36). No major integrase strand transfer inhibitor (INSTI) mutations were detected at baseline, however, 11% (4/36) harbored INSTI accessory mutations (L74M, Q95K, T97A). From week 24 onwards, eight participants (7·1%) with viral non-suppression (≥50 RNA copies/mL) had follow-up genotypes available (5/8 BIC-arm; 3/8 DTG-arm). No emergent INSTI mutations were observed, and one participant (DTG-arm) developed emergent M184V/I mutations. Conclusions In this trial setting, twice-daily bictegravir/emtricitabine/tenofovir alafenamide during rifampicin treatment maintained high rates of viral suppression with no emergent INSTI resistance through 48 weeks. These findings support bictegravir as an alternative to dolutegravir among adults with HIV/TB and CD4 counts ≥50 cells/mm3 receiving rifampicin-based treatment.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Benjamin Chimukangara has the highest h-index among the authors (14).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.